HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors.

Abstract
Thromboangiitis obliterans, or Buerger's disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment. Although two randomized trials have demonstrated a role for intravenous iloprost, no oral drug has yet been demonstrated to be effective in treating thromboangiitis obliterans. We present the first three reported cases of thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors, followed by a discussion of the rationale for the use of these agents in thromboangiitis obliterans.
AuthorsAryeh M Abeles, Mirela Nicolescu, Zachary Pinchover, Micha Abeles
JournalVascular (Vascular) Vol. 22 Issue 4 Pg. 313-6 (Aug 2014) ISSN: 1708-5381 [Print] England
PMID24000082 (Publication Type: Case Reports, Journal Article)
Copyright© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
Chemical References
  • Phosphodiesterase 5 Inhibitors
Topics
  • Aged
  • Female
  • Hand (blood supply)
  • Humans
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors (therapeutic use)
  • Thromboangiitis Obliterans (diagnosis, drug therapy, enzymology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: